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Objectives: Italian recommendations for human papillomavirus (HPV) immu-
nization currently consider females only. However, males can be vectors in viral 
transmission and at risk of infection. The BEST II study was designed to evaluate: 
the cost-effectiveness (CE) of different interventions targeting females as well as 
males; and the economic impact of vaccination on a wide range of HPV-induced dis-
eases. MethOds: A dynamic Bayesian Markov model was developed to investigate 
the transmission between sexual partners and the cost-effectiveness of vaccination 
targeting female and male cohorts in comparison to screening and female cohorts 
only. A range of HPV-induced diseases was considered (cervical, vaginal, vulvar, 
anal, head and neck and penile cancer, the associated pre-cancerous stages and 
anogenital warts). The process of sexual mixing was calculated based on age, gender 
and sexual behavioural specific matrices to estimate th force of infection dynami-
cally. Increased susceptibility to the virus, associated with early sexual début, a high 
number of partners, smoking and previous STDs, were included. We considered 
several scenarios; the baseline assumes universal vaccination to be implemented 
for 12-year-old females and males. The follow-up period was 55 years. Results: 
According to our preliminary analysis, universal vaccination resulted in incremental 
CE ratios (ICERs) corresponding to € 910 and € 5,770, when compared to screening-
only and female-only vaccination, respectively. We performed extensive sensi-
tivity analysis, which confirmed the good CE profile of universal vaccination in 
Italy. cOnclusiOns: A universal HPV vaccination of male and female programme 
is more cost-effective than screening and female-only vaccination when account-
ing for all HPV-related diseases. Universal vaccination programme increase herd 
immunity and provide indirect protection to unvaccinated girls against HPV. The 
herd immunity plays a significant role in the economic evaluation of HPV immuni-
zation programmes. A universal vaccination may be further useful considering that 
males are both at risk of infection and vectors in viral transmission.
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Objectives: To assess the cost-effectiveness of Bendamustine-Rituximab (BR) 
compared with Fludarabine-Rituximab (FR) treatment, in patients with Indolent 
Non-Hodgkin’s Lymphoma (INHL) that have progressed during or within six 
months of treatment with Rituximab or a Rituximab-containing Regimen in Costa 
Rica. MethOds: A three-health state cohort simulation Markov Model (progres-
sion-free, progressive disease, and death) was developed based on time-dependent 
progression-free survival and overall survival data. The time frame was lifetime (35 
years). The perspective was that of the National Health System of Costa Rica. The 
health outcomes of interest were Quality Adjusted Life Years (QALYs), Life Years 
(LYs), and Progression-free Life Years (PFLYs). Resource consumption for health 
states was elicited with the support of Latin American hematologists. Utilities for 
health states and disutility for adverse reactions were taken from published studies. 
All costs and Incremental Cost Effectiveness Ratios (ICERs) are presented in Costa 
Rican currency (Colones). Costs and outcomes were discounted at 3%. One way 
and probabilistic sensitivity (PSA) analysis were performed. Results: BR resulted 
in 4,641 QALYs/ 6,432 LYs/ and 3,564 PFLYs, per patient, respectively. FR resulted in 
3,557 QALYs/5,138 LYs and 2,047 PFLYs, per patient, respectively. Total costs were: 
76.309.813 for BR and 73.045.490 for FR. ICERs were: 3.013.664 per QALY gained, 
2.523.307 per LY gained and 2.151.945 per PFLY gained. In all outcomes, results 
were highly sensitive to Hazard Ratio of overall survival. According to the PSA, 
with QALYs as outcome, BR had a probability of 63% of being cost effective when 
considering the threshold of 3 times the Gross Domestic Product per capita (GDPPC) 
of Costa Rica (14.140.792). cOnclusiOns: BR can be considered very cost-effective 
compared with FR in the study population (INHL) in Costa Rica, according to the 
threshold suggested by the World Health Organization [very cost effective below 
1 GDPPC (4.713.597)].
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Objectives: The objective of this study is to evaluate cost-effectiveness of abirater-
one plus prednisolone compared to prednisolone alone in Japan. We presented the 
result of the cost-effectiveness analysis of abiraterone acetate in 2013 ISPOR Europe 
Congress. In the present study we reanalyze the cost-effectiveness of abiraterone 
by referencing the real world resources using a Japanese claim data set. MethOds: 
Cost-effectiveness analysis was performed using a Markov model based on data 
from the randomized controlled trial (COU-AA-301 study) and literature review 
conducted from the public health care payer’s perspective. The abiraterone plus 
prednisolone was compared with prednisolone alone. The base case was assumed 
to be a 72 year-old man with metastatic castration-resistant prostate cancer (CRCP). 
The model used a time horizon of 10 years. Outcomes were measured in quality-
Medicare beneficiaries aged ≥ 66 diagnosed with HM between January 1, 1995 and 
December 31, 2007, including: acute myeloid leukemia (AML, n= 10,173); chronic lym-
phocytic leukemia (CLL, n= 13,743); chronic myelogenous leukemia (CML, n= 4,169); 
Hodgkin lymphoma (HL, n= 2,252); non-Hodgkin lymphoma (NHL, n= 51,087); and 
multiple myeloma (MM, n= 18,297). We used a discrete hazard model to estimate 
survival and projected lifetime costs using a generalized linear model with a log-
link and gamma distribution. Models were adjusted for year of diagnosis, age, race, 
gender, and comorbidity. We calculated the incremental cost-effectiveness ratio 
(ICER, measured in terms of cost per life year [LY]) using cost and survival differences 
between the earliest (1995-1998) and latest (2005-2007) time periods. Costs were 
standardized to year 2010 dollars. Results: HM survival among Medicare patients 
increased during the time period studied, though gains varied by diagnosis. Care 
costs for all diagnoses also increased over time, especially for HL (from $148,000 
for individuals diagnosed during 1995-1998 to $230,000 for a 2005-2007 diagnosis) 
and NHL (from $158,000 for patients diagnosed during 1995-1998 to $247,000 for 
a 2005-2007 diagnosis). Survival gains were most cost-effective for CML ($37,877/
LY) and least cost-effective for HL ($94,859/LY). The ICERs were $43,262/LY for CLL, 
$59,355/LY for MM, $62,127/LY for NHL, and $83,392/LY for AML. cOnclusiOns: Our 
findings suggest that over a period of more than a decade, improvements in treat-
ment for HM have been associated with gains in survival, but also with substantial 
increases in health care costs. Overall, HM therapy innovations appear to provide 
good value for money among Medicare patients when evaluated using conventional 
cost-effectiveness metrics.
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Objectives: Sunitinib is one of the first targeted treatments for metastatic renal 
cell carcinoma (MRCC) and is currently considered as the standard of care for 
most of the MRCC patients in the first-line setting. Sunitinib delays disease pro-
gression, with a median overall survival of more than 2 years, improves quality 
of life and is becoming the first-line standard of care for MRCC. The introduction 
of targeted treatments, led to improvements in disease management and sur-
vival of these patients, however, with increasing cost. Purpose this reserch - to 
assess the economic value of sunitinib as first-line therapy in MRCC within the 
Kazakh health care system. MethOds: Cost-effectiveness of sunitinib has been 
assessed on several occasions and a systematic literature search was conducted 
to find all published research articles as well as all research abstracts presented 
in various congresses. An adapted Markov model with a 10-year time horizon 
was used to analyse the cost effectiveness of sunitinib vs. sorafenib (SFN) and 
bevacizumab/interferon-α (BEV/IFN) as first-line MRCC therapy from the Kazakh 
perspective. Results: Progression-free survival and overall survival data from 
sunitinib, SFN and BEV/IFN pivotal trials were extrapolated to project survival 
and costs in 6-week cycles. Results, in progression-free life-years (PFLY), life 
years (LY) and quality-adjusted life-years (QALY) gained, expressed as incremen-
tal cost-effectiveness ratios (ICER) with costs and benefits discounted annually 
approximate 3%, were obtained using deterministic and probabilistic analyses. 
Sunitinib was more effective and less costly than both SFN and BEV/IFN with 
average cost savings/patients, respectively. Using a willingness-to-pay threshold, 
sunitinib achieved an incremental net benefit compared with SFN and BEV/IFN, 
respectively. At this willingness-to-pay, the probability of sunitinib providing the 
highest incremental net benefit was 72%. cOnclusiOns: Our analysis suggests 
that sunitinib is a costeffective alternative to other targeted therapies as first-line 
MRCC therapy in the Kazakh health care setting.
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Objectives: Whether the addition of radiation therapy (RT) improves overall 
cost effectiveness in men with locally advanced prostate cancer managed with 
androgen deprivation therapy (ADT) is still unclear. Our objective was to conduct 
cost-effectiveness analysis of adding radiation therapy to androgen deprivation 
therapies in men with locally advanced prostate cancer in the U.S.A. MethOds: A 
decision analysis model was designed to compare adding RT to ADT over a 10 year 
time horizon with the third party payer’s perspective. Probabilities of treatment 
success, utilization of salvage treatments, and rates of adverse events were taken 
from published results of SPCG-7/SFUO-3 trial and NCIC CTG PR.3/MRC UK PR07 
trial. Cost inputs were based on 2010 Medicare reimbursement rates and reported 
in 2013 US dollars. Primary outcome measure was incremental cost per biochemi-
cal success (i.e. serum PSA level < 0.4 ng/ml). 50,000 U.S. dollars were considered 
willingness to pay threshold. A series of one-way sensitivity analyses and Monte 
Carlo simulation was performed by testing variations in the range of the 95% con-
fidence interval. Results: ART results in a higher biochemical success rate than 
hormonal therapy with a probability of 0.30 versus 0.21. The mean incremental 
effect was 0.6 over a 10-year period. Total cost of ART was $25,783 compared with 
costs in the ADT group of $13,427 per year, the mean incremental cost for ART ver-
sus ADT was $8,277 over 10 year period. The mean incremental cost effectiveness 
ratio was $13758 over 10 year period. Cost-effectiveness acceptability curve analysis 
resulted in > 90% probability that ART with hormonal therapy is cost-effective strat-
egy. cOnclusiOns: Study suggests that adding RT to ADT is cost effective strategy 
compared to ADT alone based upon the decision analysis model for appropriate men 
with locally advanced prostate cancer. The study limitations and treatment dosage 
should be considered before applying the results of the study.
